Maze Therapeutics: $115 Million (Series D) Raised To Develop Precision Medicine
By Amit Chowdhry ● Dec 3, 2024
Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the completion of a $115 million Series D financing that included the conversion of issued convertible notes previously purchased by existing investors. Investors Frazier Life Sciences and Deep Track Capital co-led the Series D funding. Janus Henderson Investors and Logos Capital also participated. And existing investors include Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management, GV, General Catalyst, Andreessen Horowitz (a16z), Foresite Capital, Woodline Partners LP, Casdin Capital, Piper Heartland Healthcare Capital, Moore Strategic Ventures, and other existing leading healthcare investors.